Navigation Links
MAP Pharmaceuticals to Present Data Showing Low Migraine Recurrence Rates With LEVADEX™ in FREEDOM-301 Trial
Date:10/29/2010

triptan analyses. Factors found to affect the rate of recurrence in the triptan meta-analyses include gender of the patient, age group (below 35 and above 35), and severity of headache pain at the time of treatment (moderate vs. severe). In this analysis, both age and severity of pain at time of treatment were associated with higher recurrence rates in the placebo group.

A second new analysis, "The Major Metabolite of Dihydroergotamine (DHE) After Oral Inhalation and IV Administration Does Not Significantly Contribute to the Pharmacological Activity," analyzed results of two studies and showed that the pharmacologic contribution of DHE's primary metabolite is minimal.

The seven other analyses to be presented include:

  • LEVADEX, a Novel Orally Inhaled Treatment for Acute Migraine: Efficacy and Tolerability Results of a Phase 3 Study (#462)
  • Efficacy Evaluation of LEVADEX in Treating a Broad Spectrum of Acute Migraine Attacks (#463)
  • Efficacy Evaluation of LEVADEX in Treating Resistant Migraine Including Migraine with Allodynia, Morning Migraine, Disabling Migraine and Migraine Treated Late (#464)
  • Utility of LEVADEX in Situations Where Early Intervention Paradigm is Impractical (#322)
  • Evaluation of Safety and Efficacy of LEVADEX (MAP0004) in Treating Acute Menstrual Migraine (#465)
  • Evaluation of Efficacy and Safety of LEVADEX (MAP0004) in Reversing Central Sensitization and Treating Migraine in Established Allodynic Patients (#466)
  • The Efficacy and Tolerability of LEVADEX (Orally Inhaled DHE) for the Treatment of Migraine in Subjects with Concomitant Asthma (#467)

  • About LEVADEX™ LEVADEX orally inhaled migraine therapy is a novel migraine therapy in Phase 3 development. Patients administer LEVADEX themselves using the company's proprietary TEMPO® inhaler. LEVADEX has been designed to be differentiated from existing migraine treatments. It is a novel formulation of dihydroergot
    '/>"/>

    SOURCE MAP Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/4/2015)... -- Former NASA scientist Tamim Hamid was ... discussed Theradome™, the first portable and wearable OTC hair ... firsthand how, via laser technology, Theradome™ offers individuals a ... not require surgery or medication.  "The ... the hair follicle, which is where the stem cells ...
    (Date:5/4/2015)... May 4, 2015 PAREXEL International Corporation (NASDAQ: ... the UBS Healthcare Conference on Monday, May 18, 2015, in ... and Chief Financial Officer will be making a presentation on ... A live webcast of the presentation will be available ... in the Upcoming Events portion of the main page, ...
    (Date:5/4/2015)... , May 4, 2015 Rogne Bioscience, ... psoriasis, today announced that preclinical and mechanism of action ... the Society of Investigative Dermatology (SID) Annual Meeting being ... Atlanta, Georgia . Logo - ... the development of RON2315, a novel, low MW (<1700 ...
    Breaking Medicine Technology:FOX News Features Theradome as the Take-Home Solution to Tackle Baldness 2PAREXEL International to Present at UBS Healthcare Conference 2Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2
    ... , POINT RICHMOND, Calif., Nov. 12 Transcept Pharmaceuticals, ... focused on the development and commercialization of proprietary products ... financial results for the three and nine months ended ... that on October 28, 2009, the FDA issued a ...
    ... / -- New research findings presented today ... International Conference in New York show promise in ... alternative medicine (CAM) using traditional research methods. Susan ... and Clinics of Minnesota (Children,s), presented findings on ...
    Cached Medicine Technology:Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 2Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 3Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 4Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 5Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 6Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 7Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 8Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 9Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 10Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 11Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 12New Research Shows Promise in Using Traditional Research Methods to Assess Efficacy of Complementary Therapies 2
    (Date:5/4/2015)... 05, 2015 The National Association ... Betancourt as a 2015-2016 inductee into the NAPW ... with this prestigious distinction for leadership in business. NAPW ... women, boasting more than 700,000 members and over 200 ... with this important honor," said NAPW President Star Jones. ...
    (Date:5/4/2015)... Every Friday afternoon at A Forever ... Southwest Michigan, patients and staff gather in the common ... rehabilitation program and to gain encouragement and inspiration in ... One by one, those patients who have completed their ... certificates and to share a bit about their journey ...
    (Date:5/4/2015)... Montreal, CANADA (PRWEB) May 04, 2015 ... development of innovative proofreading technologies, today announced that ... #438 at the Music City Center, in Nashville ... Proofware is the world's first true all-in-one we-based ... everyone involved in the security of their brand ...
    (Date:5/4/2015)... City, MO (PRWEB) May 04, 2015 ... vice president and chief physician executive, and William C. ... have received and accepted personal invitations from the Secretary ... National Security Forum (NSF) at the Air War College, ... is to expose influential citizens to senior U.S. and ...
    (Date:5/4/2015)... Milton Hershey School® has named J. ... the Year, recognizing his commitment to pediatric cancer research ... for MHS students. , “Dr. Graves is a tremendous ... are provided a top-notch education, a nurturing environment, and ... Pete Gurt ’85, president of MHS. “He is applying ...
    Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Gloria Betancourt, Receptionist at Consulate Health Care, into its 2015-2016 VIP Woman of the Year Circle 2Health News:A Forever Recovery Celebrates New Victories in Overcoming Addiction With Weekly Graduation 2Health News:Global Vision to Spotlight Proofware at INFO*FLEX 2015 2Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:Milton Hershey School Names 2015 Alumnus of the Year 2
    ... Enjoy Broad Choice of,Prescription Drugs, WASHINGTON, Jan. 31 ... statement on new budget,figures that report the cost of ... years than was estimated last summer:, "Part D ... drugs. New budget documents show that the overall,projected cost ...
    ... 2008. As part of its ongoing efforts to do ... and a cure for Parkinson,s disease, The Michael J. ... $3 million in total funding to four industry teams ... the clinic. The awards were granted under MJFF,s Therapeutics ...
    ... Schering-Plough,Corporation (NYSE: SGP ) today reported ... received an A-1 recommendation(1) (highest,rating) for the ... risk patients in the latest Treatment of ... Society of America (IDSA),released this month. The ...
    ... Jan. 31 Cardinal Health, a,global provider of products ... care, today announced the resignation of Matthew D.,Walter from ... quarterly dividend., "We want to thank Matt for ... John B. McCoy, chairman of the Nominating and,Governance Committee. ...
    ... Jan. 31 National opinion leaders will,convene in ... latest data,guidelines, practical applications, and strategies for the ... to make the,meeting highly interactive., The Summit ... credits sponsored,by The Dannemiller Educational Foundation, and the ...
    ... a gene that is the key switch that allows ... Much like students in a kindergarten class lining up ... identified as Smarcd3, must align correctly with two other ... as myogenesis, said principal investigator Monte Westerfield, a professor ...
    Cached Medicine News:Health News:Michael J. Fox Foundation awards up to $3 million to industry teams 2Health News:Michael J. Fox Foundation awards up to $3 million to industry teams 3Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 2Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 3Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 4Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 5Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 6Health News:Cardinal Health Announces Resignation of Director; Declares Regular Quarterly Dividend 2Health News:Dannemiller Memorial Education Foundation and GR MedEd, Inc. Announce Oncology Summit: From Discovery to Delivery 2Health News:Dannemiller Memorial Education Foundation and GR MedEd, Inc. Announce Oncology Summit: From Discovery to Delivery 3Health News:Oregon researchers find trigger gene for muscle development 2
    ... medication nebulizer achieves optimum lung penetration for ... range is 1.04-1.10 µ at 6-8 LPM. ... outlet., ,As the world leader in ... the assurance of proven technology by offering ...
    ... breakthrough continuous low-flow nebulizer performance. Patented ... technology allows for optimal medication and ... Heliox). OMNI~NEB takes on severe asthma, ... and critical care situations. Configure with ...
    ... offer a spill-proof design and effective output, ... angle. All medical nebulizers are free-standing for ... configurations are available., ,All Portex® medication ... medication nebulizers feature consistently fine misting and ...
    ... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
    Medicine Products: